High Alert
Contraindicated in:
Use Cautiously in:
prolonged use of opioids during pregnancy can result in neonatal opioid withdrawal syndrome
;CV: bradycardia, hypotension
Derm: sweating, erythema
Endo: adrenal insufficiency
GI: anorexia, constipation, dry mouth, nausea, vomiting
Local: application site reactions
MS: skeletal and thoracic muscle rigidity
Neuro: confusion, sedation, weakness, dizziness, restlessness
Resp: APNEA, bronchoconstriction, laryngospasm, RESPIRATORY DEPRESSION (INCLUDING CENTRAL SLEEP APNEA AND SLEEP-RELATED HYPOXEMIA)
Misc: allodynia, opioid-induced hyperalgesia,
physical dependence
,psychological dependence
Drug-drug:
Concurrent use of CYP3A4 inhibitors, including ritonavir, ketoconazole, itraconazole, clarithromycin, nelfinavir, nefazodone, amiodarone, diltiazem, aprepitant, fluconazole, fosamprenavir, verapamil, and erythromycin, may result in ↑ levels and ↑ risk of CNS and respiratory depression.
CYP3A4 inducers, including barbiturates, carbamazepine, efavirenz, corticosteroids, modafinil, nevirapine, oxcarbazepine, phenobarbital, phenytoin, rifabutin, or rifampin, may ↓ levels and analgesia; if inducers are discontinued or dosage ↓, patients should be monitored for signs of opioid toxicity and necessary dose adjustments should be made.
Use with benzodiazepines or other CNS depressants, including other opioids, nonbenzodiazepine sedative/hypnotics, anxiolytics, general anesthetics, muscle relaxants, antipsychotics, and alcohol, may cause profound sedation, respiratory depression, coma, and death; reserve concurrent use for when alternative treatment options are inadequate.
Drug-Natural Products:
Drug-Food:
Hepatic Impairment
Renal Impairment
Absorption: Well absorbed (92% of dose) through skin surface under transdermal patch, creating a depot in the upper skin layers. Release from transdermal system into systemic circulation ↑ gradually to a constant rate, providing continuous delivery for 72 hr.
Distribution: Widely distributed to tissues.
Half-Life: 17 hr after removal of a single application patch; ↑ to 21 hr after removal of multiple patches (because of continued release from deposition of drug in skin layers).
(analgesia)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
Transdermal | 6 hr‡ | 1224 hr | 72 hr‡ |
‡Achievement of plasma concentrations associated with analgesia. Maximal response and dose titration may take up to 6 days.
‡While patch is worn.
Instruct patient in correct method for application and disposal of transdermal system. Fatalities have occurred from children having access to improperly discarded patches.
May be worn while bathing, showering, or swimming.Advise patient that fentanyl is a drug with known abuse potential. Protect it from theft, and never give to anyone other than the individual for whom it was prescribed. Store out of sight and reach of children and in a location not accessible by others.
Caution patient that fever, electric blankets, heating pads, saunas, hot tubs, and heated water beds ↑ the release of fentanyl from the patch and can result in fatal overdose.
Inform patient of potential for neonatal opioid withdrawal syndrome with prolonged use during pregnancy. Monitor neonate for signs and symptoms of withdrawal symptoms (irritability, hyperactivity and abnormal sleep pattern, high-pitched cry, tremor, vomiting, diarrhea, failure to gain weight); usually occur the first days after birth. Monitor infants exposed to fentanyl through breast milk for excess sedation and respiratory depression.
Chronic use may ↓ fertility in women and men.NDC Code